{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-200256","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.780517+00:00","generated_at":"2026-05-31T09:24:30.753329+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Invivyd reports Q2 2024 net product revenue of $2.3M, expects 2024 revenue of $150-200M","bullets":["PEMGARDA launched commercially in Q2 2024 with $2.3M net product revenue; early Q3 commercial acceleration noted.","Cash and cash equivalents were $147.9M as of June 30, 2024; projected year-end cash at least $75M.","EUA amendment request submitted to FDA for PEMGARDA for treatment of mild-to-moderate COVID-19 in immunocompromised patients.","Next-generation molecule VYD2311 first-in-human trial dosing scheduled to begin late August 2024.","Tim Lee joined as Chief Commercial Officer; board expanded with Srishti Gupta and Kevin F. McLaughlin."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-200256","json":"https://secwatch.observer/filing/0001193125-24-200256.json","markdown":"https://secwatch.observer/filing/0001193125-24-200256.md","text":"https://secwatch.observer/filing/0001193125-24-200256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524200256/0001193125-24-200256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524200256/d878899d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:24:30.753329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}